相关实验视频

Updated: Jun 23, 2025

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

对于肌缩性侧面硬化症而言,他类药物的作用:有保护作用还是没有保护作用?

Hayder M Al-Kuraishy¹, Majid S Jabir², Ghassan M Sulaiman²

¹Department of Clinical Pharmacology and Medicine, College of Medicine, Mustansiriyah University, Baghdad, Iraq.

Frontiers in neuroscience

|June 21, 2024

概括

类他类药物是一种药物.

科学领域:

神经学神经学
药理学药理学是指药理学的学科.
神经退行性疾病神经退行性疾病

背景情况:

肌缩侧面硬化症 (ALS) 是一种渐进的运动神经元疾病,排名第三最常见的神经退行性疾病.
世界卫生组织 (WHO) 之前曾表示,他类药物可能会增加ALS风险,但最近的证据是相互矛盾的.
对于他类药物对ALS病原性的影响仍然存在争议,研究表明潜在的风险和神经保护性益处.

研究的目的:

审查和讨论他类药物在肌缩侧面硬化症 (ALS) 神经病理学中的复杂和争论的作用.
探索关于他类药物对ALS发展和进展的影响的相互矛盾的证据.
为了阐明潜在的机制,在ALS的基础上,既提议的不利和保护性效应的他类药物.

主要方法:

这是一个叙事评论,综合现有文献.
该审查审查了临床前和临床研究,元分析和系统审查.
它侧重于在ALS中提议的他类药物的作用机制.

主要成果:

关于他类药物与ALS风险的关联,存在相互矛盾的发现.
一些研究表明,他类药物可能会诱导类似于ALS的综合征,而另一些研究则表明神经保护作用.
潜在的机制包括脂质不良,炎症和肝脏X受体 (LXR) 信号.

结论:

对于他类药物在ALS病变发生过程中的确切作用尚不完全理解.
需要进一步的研究来澄清他类药物是否构成风险或提供对ALS的保护.
了解这些影响对于管理患有或有ALS风险的患者至关重要.

关键词:

肌缩性侧面硬化症 (AMLS) 是一种疾病.老化的老化衰老的老化神经退行性疾病的神经退行性疾病病变的发生和发病.类药物类药物类药物

更多相关视频

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis

Published on: July 16, 2021

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS

Published on: March 17, 2012

相关概念视频

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...

Cross-bridge Cycle

Cross-bridge Cycle

As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.

Amyloid Fibrils

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...

Lysosomal Hydrolases

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...